Avastin Lung Cancer Reimbursement Will Be Case By Case, Genentech Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says it is too early to determine the extent of off-label use of Avastin in lung cancer. Genentech will present data on use of Avastin alone, as well as in combination with Tarceva, for the treatment of lung cancer at ASCO's annual meeting in May.